PRF Technologies Ltd. Announces Commercial Collaboration Agreement with Blade Ranger to Accelerate Large-Scale DeepSolar Commercial Engagements Life Science Investing
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors Life Science Investing
Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates Life Science Investing
HCW Biologics Closes Exclusive Worldwide License for HCW11-006 - A High Potential Fusion Immunotherapeutic Life Science Investing
MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs Life Science Investing
Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson's Disease at AD/PD 2026 Conference Life Science Investing
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® for Follicular Lymphoma in Argentina and Mexico Life Science Investing
Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® in Brazil Life Science Investing
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis Life Science Investing
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates Life Science Investing
NRx Pharmaceuticals Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx's Preservative-Free Ketamine Application Life Science Investing
Greenwich LifeSciences Provides Update Showing Continued Reduction in Recurrence Rate in the Open Label Arm of FLAMINGO-01 Life Science Investing
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study in Metastatic Breast Cancer
